F. Icli Et Al. , "Adjuvant oral etoposide plus cisplatin (EoP) following sequential doxorubicin/cyclophosphamide (AC) and docetaxel (T) in early breast cancer patients with 4 or more positive lymph nodes (10 years follow-up)," BREAST , vol.20, no.2, pp.155-157, 2011
Icli, F. Et Al. 2011. Adjuvant oral etoposide plus cisplatin (EoP) following sequential doxorubicin/cyclophosphamide (AC) and docetaxel (T) in early breast cancer patients with 4 or more positive lymph nodes (10 years follow-up). BREAST , vol.20, no.2 , 155-157.
Icli, F., AKBULUT, H., Onur, H., Yalcin, B., DEMİRKAZIK, A., & ÇAY ŞENLER, F., (2011). Adjuvant oral etoposide plus cisplatin (EoP) following sequential doxorubicin/cyclophosphamide (AC) and docetaxel (T) in early breast cancer patients with 4 or more positive lymph nodes (10 years follow-up). BREAST , vol.20, no.2, 155-157.
Icli, Fikri Et Al. "Adjuvant oral etoposide plus cisplatin (EoP) following sequential doxorubicin/cyclophosphamide (AC) and docetaxel (T) in early breast cancer patients with 4 or more positive lymph nodes (10 years follow-up)," BREAST , vol.20, no.2, 155-157, 2011
Icli, Fikri Et Al. "Adjuvant oral etoposide plus cisplatin (EoP) following sequential doxorubicin/cyclophosphamide (AC) and docetaxel (T) in early breast cancer patients with 4 or more positive lymph nodes (10 years follow-up)." BREAST , vol.20, no.2, pp.155-157, 2011
Icli, F. Et Al. (2011) . "Adjuvant oral etoposide plus cisplatin (EoP) following sequential doxorubicin/cyclophosphamide (AC) and docetaxel (T) in early breast cancer patients with 4 or more positive lymph nodes (10 years follow-up)." BREAST , vol.20, no.2, pp.155-157.
@article{article, author={Fikri Icli Et Al. }, title={Adjuvant oral etoposide plus cisplatin (EoP) following sequential doxorubicin/cyclophosphamide (AC) and docetaxel (T) in early breast cancer patients with 4 or more positive lymph nodes (10 years follow-up)}, journal={BREAST}, year=2011, pages={155-157} }